[go: up one dir, main page]

MX2024011755A - Derivados sulfonamidicos como inhibidores de la cinasa dependiente de ciclina 2 (cdk2) - Google Patents

Derivados sulfonamidicos como inhibidores de la cinasa dependiente de ciclina 2 (cdk2)

Info

Publication number
MX2024011755A
MX2024011755A MX2024011755A MX2024011755A MX2024011755A MX 2024011755 A MX2024011755 A MX 2024011755A MX 2024011755 A MX2024011755 A MX 2024011755A MX 2024011755 A MX2024011755 A MX 2024011755A MX 2024011755 A MX2024011755 A MX 2024011755A
Authority
MX
Mexico
Prior art keywords
cdk2
inhibitors
dependent kinase
cyclin
sulfonamide derivatives
Prior art date
Application number
MX2024011755A
Other languages
English (en)
Inventor
Yan Lou
Original Assignee
Nikang Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nikang Therapeutics Inc filed Critical Nikang Therapeutics Inc
Publication of MX2024011755A publication Critical patent/MX2024011755A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D331/00—Heterocyclic compounds containing rings of less than five members, having one sulfur atom as the only ring hetero atom
    • C07D331/04—Four-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción proporciona ciertos derivados sulfonamídicos que son inhibidores de la cinasa dependiente de ciclina 2 (CDK2) de Fórmula (I): (ver Fórmula) (I) para el tratamiento de enfermedades que se pueden tratar mediante la inhibición de CDK2. También se proporcionan composiciones farmacéuticas que contienen tales compuestos y procesos para preparar tales compuestos.
MX2024011755A 2022-03-28 2024-09-25 Derivados sulfonamidicos como inhibidores de la cinasa dependiente de ciclina 2 (cdk2) MX2024011755A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263362036P 2022-03-28 2022-03-28
PCT/US2023/064895 WO2023192801A1 (en) 2022-03-28 2023-03-24 Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors

Publications (1)

Publication Number Publication Date
MX2024011755A true MX2024011755A (es) 2024-11-08

Family

ID=86052189

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011755A MX2024011755A (es) 2022-03-28 2024-09-25 Derivados sulfonamidicos como inhibidores de la cinasa dependiente de ciclina 2 (cdk2)

Country Status (11)

Country Link
US (1) US12331026B2 (es)
EP (1) EP4499634A1 (es)
JP (1) JP2025509886A (es)
KR (1) KR20240167846A (es)
CN (1) CN119053595A (es)
AU (1) AU2023243322A1 (es)
CA (1) CA3254713A1 (es)
IL (1) IL315603A (es)
MX (1) MX2024011755A (es)
TW (1) TW202346292A (es)
WO (1) WO2023192801A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL308314A (en) 2021-05-07 2024-01-01 Kymera Therapeutics Inc CDK2 compounds and their uses
WO2025072462A1 (en) 2023-09-27 2025-04-03 Nikang Therapeutics, Inc. Sulfonamide derivatives as cyclin-dependent kinase 2 inhibitors
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
US5266573A (en) 1989-08-07 1993-11-30 Elf Sanofi Trifluoromethylphenyltetrahydropyridines for the treatment and/or prophylaxis of intestinal motility disorders
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
IL151946A0 (en) * 2000-03-29 2003-04-10 Cyclacel Ltd 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
EP2407473A3 (en) 2002-02-01 2012-03-21 ARIAD Pharmaceuticals, Inc Method for producing phosphorus-containing compounds
IL163748A0 (en) 2002-03-05 2005-12-18 Merck Frosst Canada Inc Cathepsin cysteine protease inhibitors
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
CN102964294A (zh) 2004-09-02 2013-03-13 遗传技术研究公司 Hedgehog信号转导的吡啶基抑制剂
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
PE20090678A1 (es) 2007-09-12 2009-06-27 Genentech Inc Combinaciones de compuestos inhibidores de fosfoinositida 3-quinasa y agentes quimioterapeuticos y los metodos de uso
JP5348725B2 (ja) 2007-10-25 2013-11-20 ジェネンテック， インコーポレイテッド チエノピリミジン化合物の製造方法
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
BRPI0916356B1 (pt) 2008-07-24 2022-08-23 Nerviano Medical Sciences S.R.L 3,4-diaril pirazois como inibidores da proteína quinase
WO2010059610A1 (en) 2008-11-19 2010-05-27 Renovis, Inc. 6, 7 -dihydro- 5h- pyrrolo [3, 4-d] pyrimidin-4-yl] -quinolin-3 -ylamine compounds useful as faah modulators and uses thereof
EP2406234A1 (en) 2009-03-12 2012-01-18 GlaxoSmithKline LLC Thiazole sulfonamide and oxazole sulfonamide kinase inhibitors
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
KR101123071B1 (ko) 2009-10-23 2012-03-05 한국과학기술연구원 신규 이미다졸 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 흑색종의 예방 및 치료용 약학적 조성물
KR20140117684A (ko) 2010-06-25 2014-10-07 노파르티스 아게 단백질 키나제 억제제로서의 헤테로아릴 화합물 및 조성물
JP6013375B2 (ja) 2011-02-24 2016-10-25 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤としてのチアゾリルフェニル−ベンゼンスルホンアミド誘導体
EP2686317A4 (en) 2011-03-17 2014-08-20 Selexagen Therapeutics Inc RAF KINASE INHIBITORS
KR20160013028A (ko) 2013-05-30 2016-02-03 플렉시콘, 인코퍼레이티드 키나제 조정을 위한 화합물 및 그에 대한 적응증
CR20140051A (es) 2014-01-29 2014-05-16 Glaxosmithkline Llc Compuestos de tiazol y oxazol de bencen-sulfonamida
WO2016049565A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Compositions and methods for inhibition of ras
WO2016059548A1 (en) 2014-10-13 2016-04-21 Mylan Laboratories Ltd Processes for the preparation of dabrafenib
BR112017021869A2 (pt) 2015-04-10 2018-12-11 Araxes Pharma Llc compostos quinazolina substituídos e métodos de uso dos mesmos
US10428064B2 (en) 2015-04-15 2019-10-01 Araxes Pharma Llc Fused-tricyclic inhibitors of KRAS and methods of use thereof
CA2993013A1 (en) 2015-07-22 2017-01-26 Araxes Pharma Llc Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins
WO2017058768A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356354A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356359B1 (en) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356339A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
JP2018533939A (ja) 2015-10-19 2018-11-22 アラクセス ファーマ エルエルシー Ｒａｓの阻害剤をスクリーニングするための方法
MX2018005967A (es) 2015-11-16 2018-08-29 Araxes Pharma Llc Compuestos de quinazolina 2-sustituida que comprenden un grupo heterociclico sustituido y metodos de uso de los mismos.
WO2017100546A1 (en) 2015-12-09 2017-06-15 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
US10822312B2 (en) 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
JP7039489B2 (ja) 2016-05-18 2022-03-22 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
WO2018055097A1 (en) 2016-09-23 2018-03-29 Cellipse Lim kinase inhibitors, pharmaceutical composition and method of use in limk-mediated diseases
JP2019529484A (ja) 2016-09-29 2019-10-17 アラクセス ファーマ エルエルシー Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
EA201991528A1 (ru) 2016-12-22 2020-01-16 Эмджен Инк. БЕНЗИЗОТИАЗОЛЬНЫЕ, ИЗОТИАЗОЛО[3,4-b]ПИРИДИНОВЫЕ, ХИНАЗОЛИНОВЫЕ, ФТАЛАЗИНОВЫЕ, ПИРИДО[2,3-d]ПИРИДАЗИНОВЫЕ И ПИРИДО[2,3-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ G12C KRAS ДЛЯ ЛЕЧЕНИЯ РАКА ЛЕГКОГО, РАКА ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫ ИЛИ КОЛОРЕКТАЛЬНОГО РАКА
EP3560516A1 (en) 2018-04-27 2019-10-30 Bergen Teknologioverforing AS Combination therapy including beta-sitosterol in combination with at least one of a braf inhibitor, a mek inhibitor or an erk inhibitor and methods and use thereof
WO2020124397A1 (en) 2018-12-19 2020-06-25 Inventisbio Shanghai Ltd. C-terminal src kinase inhibitors

Also Published As

Publication number Publication date
JP2025509886A (ja) 2025-04-11
KR20240167846A (ko) 2024-11-28
AU2023243322A1 (en) 2024-10-03
IL315603A (en) 2024-11-01
US20230303509A1 (en) 2023-09-28
CN119053595A (zh) 2024-11-29
CA3254713A1 (en) 2023-10-05
EP4499634A1 (en) 2025-02-05
US12331026B2 (en) 2025-06-17
WO2023192801A1 (en) 2023-10-05
TW202346292A (zh) 2023-12-01

Similar Documents

Publication Publication Date Title
MX2024011755A (es) Derivados sulfonamidicos como inhibidores de la cinasa dependiente de ciclina 2 (cdk2)
GEAP202315746A (en) Protein tyrosine phosphatase inhibitors
MX2022008627A (es) Pirazolo-pirimidinas sustituidas y usos de las mismas.
SA523440367B1 (ar) مشتقات تترازول كمثبطات لمستقبل عابر أنكيرين قوي 1
MD20210033A2 (ro) Compuşi, compoziţii şi metode pentru modularea activităţii CDK9
MX2023011829A (es) Derivados de uracilo como inhibidores de trpa1.
EA202092326A1 (ru) Производные буметанида для лечения гипергидроза
EA202090900A1 (ru) Ингибиторы иммунопротеасом
MX2023004008A (es) Derivados de tetrazol como inhibidores de trpa1.
MX2024009105A (es) Inhibidores de las cinasas cdk4/6.
CL2025000672A1 (es) Compuestos derivados de aminopirimidina, inhibidores de cdk2; composición farmacéutica; uso para tratar cáncer.
EA201992090A1 (ru) ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
BR112023015342A2 (pt) Derivados de 3h,4h-[2,3-d]-pirimidin-4-ona como inibidores de trpa1
MX2023003516A (es) Inhibidores no covalentes de la cinasa dependiente de ciclina 7 (cdk7).
SA522441973B1 (ar) Trpa1 مشتقات تترازول كمثبطات لـ
SA522441965B1 (ar) Trpa1 مشتقات تترازول كمثبطات لـ
MX2025013985A (es) Inhibidores de prmt5
MX2023014784A (es) Preparacion de derivados de compuestos 1,2-diaminoheterociclicos sustituidos y su uso como agentes farmaceuticos.
EA202190452A1 (ru) Ингибиторы cdk8/19
EA202192414A1 (ru) Соединения-ингибиторы натрий-водородного обменника 3
GEAP202516742A (en) Cyclin-dependent kinase 7 inhibitors
MX2023007291A (es) Derivados de 4-(pirazol-5-il)-indol macrociclicos ramificados como inhibidores de mcl-1.
CL2025003313A1 (es) Compuestos derivados de feniloxazolona sustituida.
EA202190690A1 (ru) Борсодержащие ингибиторы pde4
BR112021020637A2 (pt) Derivados de tetra-hidro-1h-ciclopenta[cd]indeno como inibidores de fator -2(alfa) induzível por hipóxia